“There are more adults with diabetes in China than anywhere in the world, and we are delighted that the CFDA’s approval brings the availability of Tresiba in China one step closer,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. “Tresiba gives physicians and people with diabetes a new treatment option that provides equivalent reductions in blood glucose levels and significantly lower risk of hypoglycaemia.”

China has over 100 million people living with diabetes, and the number is expected to grow to more than 150 million people by 2040.9 Tresiba is expected to launch in China in Q1 2018, the company said.